- Conditions
- Geographic Atrophy
- Interventions
- NGM621
- Biological
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 9,285
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pathogen Resistance, Pneumococcal Infection, Pneumonia
- Interventions
- Colistimethate sodium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Tumor, Solid
- Interventions
- BDB001 (EIK1001), Atezolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- agenT-797
- Drug
- Lead sponsor
- MiNK Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Boston, Massachusetts • Cincinnati, Ohio
- Conditions
- Gastroenteritis Escherichia Coli
- Interventions
- Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- HIV Infections
- Interventions
- CCR5mAb004
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Fort Lauderdale, Florida + 4 more
- Conditions
- Tuberculosis
- Interventions
- PA-824
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Recurrent Head and Neck Cancer
- Interventions
- Ad/PNP, Fludarabine Phosphate
- Biological · Drug
- Lead sponsor
- GeoVax, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Stanford, California • Atlanta, Georgia • Philadelphia, Pennsylvania
- Conditions
- Solid Neoplasms
- Interventions
- Dazostinag, Pembrolizumab, Platinum, 5-fluorouracil
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 26
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 20 more
- Conditions
- Stroke
- Interventions
- Full-pressure ECP, Sham-pressure ECP
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California
- Conditions
- Cardiac Arrest
- Interventions
- HBN-1
- Drug
- Lead sponsor
- Hibernaid, Inc
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Portland, Maine • Pittsburgh, Pennsylvania
- Conditions
- Healthy
- Interventions
- Atorvastatin, ASC42
- Drug
- Lead sponsor
- Gannex Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
- Interventions
- HBI-2376
- Drug
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 11
- States / cities
- Duarte, California • Encinitas, California • Fullerton, California + 7 more
- Conditions
- Healthy
- Interventions
- PF 06260414 solid dose formulation, PF-06260414 nanosuspension
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
- Interventions
- SHY-ONC6
- Drug
- Lead sponsor
- SHY Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Houston, Texas • San Antonio, Texas
- Conditions
- Tumors
- Interventions
- Lenvatinib, Midazolam
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease
- Interventions
- Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells, Busulfan, Palifermin, Filgrastim, Plerixafor
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Burns
- Interventions
- cNP8, Placebo
- Drug · Other
- Lead sponsor
- Neomatrix Therapeutics, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
- Interventions
- Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
- Conditions
- Advanced Solid Tumors
- Interventions
- TP-3654
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- Houston, Texas • Salt Lake City, Utah • Charlottesville, Virginia
- Conditions
- Solid Tumor, Adult
- Interventions
- KQB198, Osimertinib, Amivantamab
- Drug
- Lead sponsor
- Kumquat Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more
- Conditions
- Healthy
- Interventions
- azelaic acid pre foam formulation, Vehicle pre foam formulation, Water
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy
- Interventions
- V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Anaheim, California • Hallandale, Florida • Hollywood, Florida + 7 more
- Conditions
- Absorption, Metabolism, Excretion
- Interventions
- Simufilam
- Drug
- Lead sponsor
- Cassava Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin